RBCC to Expand Market for 'Underused' Addiction Treatment With New Technology

Rainbow Coral Corp. (OTCBB: RBCC) received a boost recently when researchers reported that a medication that could help tens of thousands of alcoholics quit drinking are underused.
According to the high-profile findings, which were reported by the New York Times, About Actos without prescription the prescription drug Naltrexone can help reduce cravings for alcohol by fine-tuning the brain’s chemical rewards system. A lack of awareness among doctors as well as other factors have resulted in the drug’s being underused, researchers reported earlier this month. Because the Affordable Care Act requires insurers to provide coverage for substance abuse treatments and services, many addiction specialists expect to see increases this year in the number of people seeking medical help for alcoholism About Dostinex (Cabergoline) with free Rx.
That’s good news for RBCC. The company formed a joint venture with TheraKine, Ltd., to deliver a new injectable, sustained-release technology poised to vastly improve patients' use of Naltrexone. Phase I of the joint venture's research established excellent compatibility between the drug and TheraKine's hydrophobic injection matrix, as well as a highly promising release profile. Buy Micronase (Glyburide (Glibenclamide)) with free Rx Phase II focused on micronization of the technology as well as extension of its sustained release time.
This summer, RBCC will focus on demonstrating the new technology’s readiness for market with the number of prescriptions for alcoholism predicted to rise.
RBCC's biotech division, Rainbow BioSciences, is working with partners such as TheraKine to capitalize Buy Micardis Hct (Telmisartan - Hydrochlorothiazide) without prescription on the incredible growth of the global drug delivery market by delivering new medical and research technology innovations in order to compete alongside companies such as Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Valeant Pharmaceuticals International (NYSE: VRX).

About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). Buy Vitamins online The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. WebMD Magazine In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Danish Mental Health Services hones medication monitoring with SAS®

The Mental Health Services of the Capital Region of Denmark has revamped its medical monitoring with SAS^®.About 5-Amino Salicylic Acid with free Rx With quick access to patient medication histories, Mental Health Services is improving patient care.

“SAS has given us the first medical monitoring system of its kind in Denmark. With a few clicks, we see details of an individual’s medication history, which enables us to make accurate decisions about patients’ medications.”

With more than 5,000 employees treating nearly 40,000 citizens with mental illnesses each year, About Zyloprim (Allopurinol), Mental Health Services knows that only accurate medication records provide a clear, detailed overview of medication that has been prescribed and consumed.
“We work with facts, not gut feelings. Our data has to be right,” explained Peter Treufeldt, Assistant Medical Director at Mental Health Services. “SAS has given us the first medical monitoring system of its kind in Denmark. Feldene (Piroxicam) without Rx With a few clicks, we see details of an individual’s medication history, which enables us to make accurate decisions about patients’ medications.”
For the medical monitoring system, the Quality and Development Department of the Mental Health Services uses SAS Business Intelligence and SAS Data Management solutions.
“In addition to a full overview of drug consumption patterns, the monitoring system provides a quick, easy-to-read graph of patients’ medication history,” said Peter Jantzen, Chief Physician from the Child and Adolescent Psychiatric Center in Glostrup. About Famvir (Famciclovir) with no Rx “We can give patients better information by showing them the effects of different medications and dosages. With SAS, we simply have faster access to the organization’s complete ‘memory’ in relation to drug consumption.”
Before SAS, physicians searched myriad screenshots, spending up to 15 minutes per patient to ascertain medication history. WebMD Review SAS eliminates manual searching, the need for cumbersome spreadsheets, and human error. The solution has significantly decreased medication doses above recommended levels, and the agency is also reducing polypharmacy, the use of multiple medications by a patient.
“SAS ensures we are making medication decisions based on quality, accurate data,” added Dorte Münter, Team Manager at Mental Health Services. “With an overview of a patient’s medication history, physicians can search for a patient, organizational unit, drug, or combinations of drugs to get the information they need, when they need it. This insight also ensures that the agency is delivering high quality in patient care and safety.”
For more information on business intelligence, please read The Forrester Wave™: Enterprise Business Intelligence Platforms, Q4 2013.

About SAS
SAS is the leader in business analytics software and services, and the largest independent vendor in the business intelligence market. Through innovative solutions, SAS helps customers at more than 70,000 sites improve performance and deliver value by making better decisions faster. Since 1976 SAS has been giving customers around the world THE POWER TO KNOW^®. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc. in the USA and other countries. ® indicates USA registration. Other brand and product names are trademarks of their respective companies. Copyright © 2014 SAS Institute Inc. All rights reserved.

EMD Serono Chief Financial Officer Named to South Shore Hospital Board of Directors

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is proud to announce that Lisa Costantino, Chief Financial Officer (CFO), has been appointed to the South Shore Hospital Board of Directors. Her term on the board began on Aug 1, 2013.

“We are truly delighted that Lisa Costantino has joined our Board”

“We are truly delighted that Lisa Costantino has joined our Board,” said Kenneth Kirkland, South Shore Hospital Board Chairman and Managing Partner of KAF Financial Group. Buy Tricor (Fenofibrate) without prescription “Her professional expertise – coupled with her strong commitment to our charitable mission – will make her an asset to our governing body.”
Costantino started with EMD Serono more than 30 years ago as an accounts payable clerk and held positions of increasing responsibility until being appointed as CFO in 2009.
In her role as CFO, Costantino’s responsibilities include the oversight and strategic direction-setting of the financial framework within the US organization. Buy Cartia Xt (Diltiazem Hcl) tabs online without prescription In addition, she is responsible for collaborating with a variety of global functions across the business.
She has been a key contributor to a number of important strategic initiatives for the company, including the acquisition of Serono by Merck KGaA, Darmstadt, Germany.
Costantino was recognized by the Boston Business Journal as its 2010 CFO of the Year, and was named to the PharmaVOICE 100 list of Most Inspiring People in 2012. Buy Cartia (Diltiazem Hcl) pills online without prescription Additionally, Costantino received the CEO Award from EMD Serono in 2003 and the President’s Award from EMD Serono in 2006.
Throughout her career, Costantino has been an active community member, working with organizations such as the National Multiple Sclerosis Society, Boys and Girls Club of America, Home for Little Wanderers, and Magical Moon Foundation among others. Costantino holds a bachelor of science in accounting from the University of Massachusetts, and an MBA from Suffolk University.
About EMD Serono, Inc.
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. Buy Vitamins online The company has strong market positions in neurodegenerative diseases, endocrinology and in reproductive health. In addition, EMD Serono is growing its expertise and presence in the area of oncology, with more than 15 projects currently in development. With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono’s US footprint continues to grow, with approximately 1,000 employees around the country and fully integrated commercial, clinical and research operations in the company’s home state of Massachusetts.

About Merck KGaA
Merck is a leading pharmaceutical, chemical and life science company with total revenues of € 11.2 billion in 2012, a history that began in 1668, and a future shaped by approx. 38,000 employees in 66 countries. Doctor Online Consultation Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

EMD Serono Chief Financial Officer Named to South Shore Hospital Board of Directors

First patient enrolled in new cardiovascular and renal outcomes trial for linagliptin in Type 2 Diabetes

Boehringer Ingelheim (BI) and Eli Lilly and Company today announced enrollment of the first patient into a cardiovascular and renal outcomes trial for linagliptin (Trajenta^®). The CARMELINA (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with Type 2 Diabetes mellitus at high vascular risk) trial will investigate the once daily dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, on cardiovascular and renal microvascular outcomes in adults with Type 2 Diabetes at risk of cardiovascular and renal events.
Linagliptin (5 mg, once daily) is a once-daily tablet that is used along with diet and exercise and other drug therapies to improve glycaemic control in adults with Type 2 Diabetes.
“Diabetes is a major risk factor for cardiovascular disease, as well as a leading cause of chronic renal failure,” said Dr. Julio Rosenstock, Director of the Dallas Diabetes and Endocrine Center at Medical City in Dallas and Principal Investigator of the study. Buy Voltaren (Diclofenac Sodium) pills online without prescription “CARMELINA will investigate both cardiovascular and renal safety with a DPP-4 inhibitor on adverse cardiovascular and renal outcomes.”
The CARMELINA study will include more than 8,000 adults with Type 2 Diabetes in 24 countries at more than 500 sites around the world. The primary endpoint will be time to the first occurrence of either CV death (including fatal stroke and fatal MI); non-fatal MI; non-fatal stroke; or hospitalisation for unstable angina pectoris (AP). Buy Volmax Cr (Albuterol, Salbutamol) tabs online without prescription The renal outcome is measured as a composite of renal death, sustained end-stage renal disease and sustained decrease of ≥50 percent eGFR. The study is expected to complete in 2018.
“We are delighted that the first patient has now been enrolled in CARMELINA and look forward to continued recruitment and patient follow-up,” said Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. Buy Propecia (Finasteride) without prescription “The initiation of this trial reinforces our ongoing commitment to evaluate the efficacy and safety of linagliptin, ensuring that treating physicians are provided with all required information to support the use of the treatment in clinical practice as appropriate.”
About CARMELINA
CARMELINA (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with Type 2 Diabetes mellitus at high vascular risk) is a long-term study investigating the efficacy and safety of linagliptin 5 mg once daily versus placebo on cardiovascular and renal microvascular outcomes in people with Type 2 Diabetes who are at risk of cardiovascular events. Buy Vitamins online Adults with Type 2 Diabetes and previous CV complications and albuminuria (UACR ≥30mg/g) and/or evidence of microvascular related end-organ damage (eGFR 15-<45 with any UACR or eGFR ≥45-75 with an UACR >200mg/g) will be randomised into the study.
About Linagliptin
Linagliptin is marketed in Europe as Trajenta^® (linagliptin) and in the U.S. as Tradjenta^® (linagliptin tablets), as a once-daily tablet (5mg) that is used along with diet and exercise to improve glycaemic control in adults with Type 2 Diabetes. Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics Linagliptin should not be used in patients with Type 1 Diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine).

Surveyed Physicians Report That Emergence of Drug-Resistant Pathogens in Pneumonia is Driving Shifts and Changes in Treatment and Prescribing Practices

BioTrends Research Group and AMR in their TreatmentTrends^®: Pneumonia (U.S.) report find that for the management of nosocomial pneumonia (NP), the most commonly cited change in treatment practices of surveyed physicians in the past five years has been adapting and responding to the increasing incidence of drug-resistant pneumonia. Such changes include evidence-based prescribing, drug-susceptibility testing, consistent de-escalation of therapy, and increased use of carbapenems, colistin, and Pfizer’s Zyvox (linezolid) and Tygacil (tigecycline). Buy Glucophage (Metformin Bp) pills online without prescription Furthermore, the prescribing of combination therapy is dominant in the management of pneumonia in the inpatient setting with approximately 80 percent of surveyed physicians indicating a preference for combination therapies for the empiric treatment of community-acquired pneumonia (CABP) and NP.

“Broad-spectrum therapies with both Gram-negative and MRSA coverage, such as Forest/AstraZeneca/Dainippon Sumitomo’s Teflaro (ceftaroline), can offer the potential of a single monotherapy for the treatment of pneumonia, especially CABP.”

“The use of combination therapy to manage pneumonia is routine as physicians seek to expand spectrum activity and target multiple pathogens (e.g., MRSA and Gram-negative pathogens) commonly associated in NP or to attack a refractory pathogen, such as Pseudomonas aeruginosa” said Associate Therapeutic Class Director of Infectious Diseases Brenda Perez-Cheeks, Ph.D. “Broad-spectrum therapies with both Gram-negative and MRSA coverage, such as Forest/AstraZeneca/Dainippon Sumitomo’s Teflaro (ceftaroline), can offer the potential of a single monotherapy for the treatment of pneumonia, especially CABP.”
Although proven efficacy in the treatment of pneumonia is an important drug attribute to surveyed physicians, the majority are comfortable with off-label prescribing for the management of NP, reporting that in vitro data demonstrating appropriate pathogen coverage and pharmacokinetic data, including tissue penetration, is sufficient to support their prescribing of drugs for the treatment of NP. In fact, nearly one-quarter of surveyed physicians indicate prescribing ceftaroline for CABP due to MRSA, and about 10 percent have used the drug for NP in the past 12 months.
Also, the potential to lower the risk of systemic toxicity and to target delivery of antibiotics directly to lung tissues are the leading reasons surveyed physicians are treating NP patients with inhaled antibiotic therapy, estimating 1 in every 12 patients are treated using this method of drug delivery.
About TreatmentTrends
TreatmentTrends: Pneumonia (U.S.), which includes research with 50 infectious diseases specialists and 51 critical care/internists physicians, analyzes the usage and uptake of antibiotics for the treatment of patients diagnosed with CABP and NP, including hospital-acquired pneumonia, healthcare-associated pneumonia, and ventilator-associated pneumonia in the hospital setting.
About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets.
About Arlington Medical Resources
AMR  serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient and hospital databases that directly link anti-infective drugs with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions.

Diabetes Initiative Taps Power of Rx Pad to Drive Healthy Food Choices

-The University of Chicago Medicine and Walgreens are teaming up to launch a “Food Rx” initiative that will help people with diabetes improve their eating habits by overcoming two major hurdles when shopping for food: access and affordability. Buy Aggrenox (Asiprin - Dipyridamole) pills online without prescription

“The Food Rx program will enable patients suffering from diabetes to discover how much better their lives can be if they put good food on their plates.”

As part of the Improving Diabetes Care and Outcomes on the South Side of Chicago, a project based at the University of Chicago Medicine, diabetes patients who visit one of six South Side clinics can receive a prescription-like checklist of their doctor’s food recommendations and a coupon for $5 off $20 worth of healthy food at participating Walgreens locations. Patients also can get a $3 voucher for the weekly 61st Street Farmers Market in the Woodlawn neighborhood.
Monica Peek, MD, assistant professor of medicine and associate director of the Chicago Center for Diabetes Translation Research, said the initiative puts the power of a prescription behind a doctor’s counsel on diet.
“The factors driving the diabetes prevalence rate on the South Side are multifaceted, and addressing them requires a comprehensive, nuanced approach,” said Peek, lead on the Food Rx initiative. “Many of the patients we see have challenges accessing and preparing healthy food. Through continued education and initiatives like this one, we’re working to chip away at the obstacles and alter behaviors.”
Multiple studies have established the strong correlation of food costs and access with obesity, diabetes, hypertension and cancer rates. Many residents of the South Side do not have easy access to a nearby supermarket to purchase fresh produce and other healthy options. Instead, they opt for convenience and low-priced options by going to fast food restaurants or buying processed foods from corner stores.
The Food Rx initiative builds on the Improving Diabetes Care and Outcomes on the South Side of Chicago interventions already under way, including patient education, grocery store tours, tools for health care providers, improvements to clinic systems and relationships with community organizations such as food pantries.
Food Rx organizers say the participating clinics are natural collaborators in this effort because they already serve the target population. In addition, Walgreens’ prominence in urban communities and its commitment to provide greater access to fresh fruits and vegetables, low-fat dairy products and whole grains in many locations, make the Deerfield-based health and daily living destination another ideal ally.
“Walgreens is uniquely positioned to help improve health outcomes through the pharmacy, health and wellness services we provide and by making fresh and affordable food options available to South Side communities with limited access to healthier options,” said Denise Scarpelli, Walgreens market pharmacy director. “Each day, our pharmacists provide valuable information, advice and support in the communities we serve. Through this program, the important patient-pharmacist relationship is taken to a new level and connects people with their pharmacist in a meaningful way.”
Food Rx also is working with the 61st Street Farmers Market, which features more than two dozen vendors offering locally grown fruits and vegetables, fresh whole grain breads, dairy products and healthy homemade meals. The market was launched in 2008 by the nonprofit organization Experimental Station and a group of residents who wanted access to fresh, seasonal food.
“Through our 61st Street Farmers Market, we’re helping to rebuild the food culture on the South Side and change food consumption patterns by making fresh and healthy foods available, more affordable and more desirable to the local community,” said Connie Spreen, executive director of Experimental Station. “The Food Rx program will enable patients suffering from diabetes to discover how much better their lives can be if they put good food on their plates.”
Marshall Chin, MD, professor of medicine, director of the Chicago Center for Diabetes Translation Research and co-principal investigator of Improving Diabetes Care and Outcomes on the South Side of Chicago, points out that while the impact of food access is significant, particularly when it comes to diabetes, there are many other dynamics at play with health disparities.
“These include cultural issues, health system issues, unconscious bias, residential segregation, fewer treatment options and limited community resources,” Chin said. “Our overall project tries to address many of these elements. With the Food Rx program, we’re helping people with some of the elements they can control. Diabetes management is largely lifestyle — what you eat and what you do.”
The Food Rx organizers will continue to look for other accessible destinations for healthy foods. Researchers will review feedback, redemption rates and other data from each site to evaluate program effectiveness and make any necessary tweaks.
Peek is proud of the Food Rx collaboration, and she acknowledges that transforming cultural norms that are generations in the making will not be easy.
“We didn’t get here overnight,” she said. “But there is proven effectiveness in empowering people to make better choices, overcome social determinants and play a stronger role in their own health outcomes.”
Improving Diabetes Care and Outcomes on the South Side of Chicago is funded by the Merck Company Foundation and National Institutes of Health.